NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis.

Jacqueline G O'Leary,Puneeta Tandon,Ram M Subramanian,Leroy R Thacker,Patrick S Kamath,Guadalupe Garcia‐Tsao,Scott W Biggins,Florence Wong,Jasmohan S Bajaj,Paul Thuluvath,Michael B Fallon,Benedict Maliakkal,Jennifer Lai,K Rajender Reddy,Hugo E Vargas

doi:10.1002/hep.29773

NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis.

Jacqueline G O'Leary, Puneeta Tandon + Show 13 more

https://doi.org/10.1002/hep.29773

Copy DOI

Journal: Hepatology	Publication Date: Apr 19, 2018
Citations: 196

Affiliation: Baylor University Medical Center, University of Alberta, Emory University, Virginia Commonwealth University, Mayo Clinic, Yale University, University of Colorado Denver, University of Toronto, Mercy Medical Center, University of Houston, University of Rochester, University of California, San Francisco, University of Pennsylvania

#Liver Disease Score #Extrahepatic Organ Failures + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Although infection status remains an important predictor of death, NACSELD-ACLF was independently validated in a separate large multinational prospective cohort as a simple, reliable bedside tool to predict 30-day survival in both infected and uninfected patients hospitalized with a diagnosis of cirrhosis. (Hepatology 2018;67:2367-2374).

Full Text